Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.76 |
| ▸ | PLAT | P00750 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | STAT3 | P40763 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2122607 | 0.92 | GRM2 (0.63) | GRM2PLATLMNAPKMHTR2C | |
| SCHEMBL13180434 | 0.91 | GRM2 (0.63) | GRM2PLATLMNAPKMHTR2C | |
| SCHEMBL3090130 | 0.88 | GRM2 (0.62) | GRM2PLATPKMHTR2CALDH1A1 | |
| SCHEMBL2123223 | 0.88 | GRM2 (0.58) | GRM2LMNAPKMALDH1A1MAPT | |
| SCHEMBL2124540 | 0.86 | GRM2 (1.00) | GRM2PLATHTR2CALDH1A1SCN5A | |
| SCHEMBL2124468 | 0.86 | GRM2 (0.66) | GRM2PLATHTR2CALDH1A1SCN5A | |
| SCHEMBL1003705 | 0.83 | GRM2 (0.53) | GRM2LMNAPKMALDH1A1SCN5A | |
| SCHEMBL8120477 | 0.83 | GRM2 (0.55) | GRM2PLATALDH1A1SCN5ASCN1A | |
| SCHEMBL13042591 | 0.82 | GRM2 (0.55) | GRM2PLATALDH1A1SCN5ANPC1 | |
| SCHEMBL2585975 | 0.82 | GRM2 (0.92) | GRM2HTR2CALDH1A1SCN5ASTAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2442649-A1 | THE USE OF METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS FOR REDUCING NICOTINE DEPENDENCE | AstraZeneca AB (SE) | 2012-04-25 | — | — | EP | claimed |
| WO-2010148074-A1 | THE USE OF METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS FOR REDUCING NICOTINE DEPENDENCE | Astrazeneca Pharmaceuticals (US) | 2010-12-23 | — | — | WO | claimed |
| US-20100280082-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators | ASTRAZENECA AB (SE) | 2010-11-04 | — | — | US | claimed |
| US-7799792-B2 | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators 841 | ASTRAZENECA AB (SE) | 2010-09-21 | — | — | US | claimed |
| EP-2167501-A1 | METABOTROPIC GLUTAMATE RECEPTOR OXADIAZOLE LIGANDS AND THEIR USE AS POTENTIATORS - 841 | AstraZeneca AB (SE) | 2010-03-31 | — | — | EP | claimed |
| WO-2008150232-A1 | METABOTROPIC GLUTAMATE RECEPTOR OXADIAZOLE LIGANDS AND THEIR USE AS POTENTIATORS - 841 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | claimed |
| US-20080306088-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators 841 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | claimed |
| EP-2444399-B1 | Oxadiazole derivatives and their use as metabotropic glutamate receptor -842 potentiators | ASTRAZENECA AB (SE) | 2014-11-26 | — | — | EP | disclosed |
| EP-2167502-B3 | OXADIAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS - 842 | ASTRAZENECA AB (SE) | 2013-07-10 | — | — | EP | disclosed |
| US-8377939-B2 | Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators 842 | ASTRAZENECA AB (SE) | 2013-02-19 | — | — | US | disclosed |
| US-8377940-B2 | Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators—842 | ASTRAZENECA AB (SE) | 2013-02-19 | — | — | US | disclosed |
| EP-2167502-B1 | OXADIAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS - 842 | ASTRAZENECA AB (SE) | 2012-09-19 | — | — | EP | disclosed |
| EP-2442649-A1 | THE USE OF METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS FOR REDUCING NICOTINE DEPENDENCE | AstraZeneca AB (SE) | 2012-04-25 | — | — | EP | disclosed |
| EP-2167502-A1 | OXADIAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS - 842 | AstraZeneca AB (SE) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008150232-A1 | METABOTROPIC GLUTAMATE RECEPTOR OXADIAZOLE LIGANDS AND THEIR USE AS POTENTIATORS - 841 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| US-20080306077-A1 | Oxadiazole Derivatives and Their Use as Metabotropic Glutamate Receptor Potentiators 842 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| WO-2008150233-A1 | OXADIAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS - 842 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| US-20080306088-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators 841 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306088-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators 841 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306088-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators 841 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306077-A1 | Oxadiazole Derivatives and Their Use as Metabotropic Glutamate Receptor Potentiators 842 | GRM1, GRIN1, GRM2 | GRM2 3/4885PLAT 4686/4885LMNA 4855/4885 |
| US-20100280082-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators | GRM1, GRM3, GRM2 | GRM2 3/4885PLAT 4735/4885LMNA 4865/4885 |
| US-20080306088-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators 841 | GRM1, GRIN1, GRM3 | GRM2 5/4885PLAT 4629/4885LMNA 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.